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Abstract: Ceftaroline is an advanced-generation cephalosporin antibiotic recently approved by 
the US Food and Drug Administration for the treatment of complicated skin and skin-structure 
infections (cSSSIs). This intravenous broad-spectrum antibiotic exerts potent bactericidal   activity 
by inhibiting bacterial cell wall synthesis. A high affinity for the penicillin-binding protein 2a 
(PBP2a) of methicillin-resistant Staphylococcus aureus (MRSA) makes the drug especially 
beneficial to patients with MRSA cSSSIs. Ceftaroline has proved in multiple well-conducted 
clinical trials to have an excellent safety and efficacy profile. In adjusted doses it is also recom-
mended for patients with renal or hepatic impairment. Furthermore, the clinical effectiveness 
and high cure rate demonstrated by ceftaroline in cSSSIs, including those caused by MRSA 
and other multidrug-resistant strains, warrants its consideration as a first-line treatment option 
for cSSSIs. This article reviews ceftaroline and its pharmacology, efficacy, and safety data to 
further elucidate its role in the treatment of cSSSIs.
Keywords: ceftaroline, cephalosporin, complicated skin and skin-structure infections, cSSSIs, 
MRSA, Teflaro®
Overview of complicated skin and skin-structure 
infections
Complicated skin and skin-structure infections (cSSSIs) are severe dermatologic 
infections either involving deep soft tissue (fascia and/or muscle layers), requiring 
significant surgical intervention, or existing in combination with significant 
underlying disease that complicates the response to treatment.1 The US Food and 
Drug Administration (FDA) recently termed these infections “acute bacterial skin and 
skin-structure infections” (ABSSSIs) based on their predominant bacterial etiology.2 
Other national or international classification and nomenclature groups often refer to 
these infections as complicated skin and soft tissue infections (cSSTIs).3,4
Microbiology of cSSSIs
The microbiologic causes of cSSSIs are diverse, with aerobic Gram-positive cocci 
most commonly isolated from these infections, specifically Staphylococcus aureus. 
Gram-negative bacilli, anaerobic bacteria, and other mixed microorganisms may 
also be involved (Table 1).5–15 In the US, studies have reported methicillin-resistant 
S. aureus (MRSA) as the leading cause of cSSSIs, with MRSA isolated in almost 
60% of cases.16,17 Community-acquired (CA) cSSSIs usually involve infection with 
S. aureus, Streptococcus pyogenes, or enterococci. One US study reported the MRSA 
USA300 clone as the predominant strain causing CA-MRSA cSSSIs.18 A recent 
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Japanese study indicating that overuse of over-the-counter 
triple antibiotic creams in the treatment of minor cuts and 
scrapes may influence the emergence of MRSA USA300 
raises significant concerns.19 Hospital-acquired (HA) cSSSIs 
usually involve infection with S. aureus, Pseudomonas 
aeruginosa, enterococci, Escherichia coli, and other 
Enterobacteriaceae, with increased prevalence of MRSA 
observed in hospitals as well as the community.8,11,12
Management of cSSSIs
Although cSSSIs arise in both communities and hospitals, 
they generally require initial and definitive treatment in a 
hospital setting due to their severity and potential for seri-
ous complications. A US hospital-based study reported 
  secondary bacteremia in 47.8% of patients with cSSSIs, 
resulting in a higher mortality rate among bacteremic patients 
than nonbacteremic patients (7.9% vs 1.0%, respectively).20 
  Bacteremia in cSSSIs is also associated with an almost 
fourfold increase in mortality rate when initial antibiotic 
therapy fails in comparison to successful initial antibiotic 
therapy (1.7% vs 0.5%, respectively) and increased length 
of hospital stay and costs.20–22
Definitive antimicrobial therapy is pathogen-specific 
based on culture results, antimicrobial susceptibility, and 
the clinical response of the infection to empirical therapy. 
Rapidly advancing infections constitute the need for surgical 
exploration with histopathological examination to identify 
necrotizing processes. If severe, rapidly advancing   infections 
may require extensive debridement and alterations to subse-
quent antimicrobial therapy.5
Limited antimicrobial agents are available for the 
  treatment of cSSSIs due to a combination of the   increasing 
prevalence of antimicrobial resistance in bacteria and a 
diminished industry focus on antimicrobial drug research 
and development;23 thus, successful treatment with approved 
antimicrobial compounds remains a challenge. Because 
of the high prevalence of MRSA in skin and soft tissue 
infections presenting to hospitals, empirical therapy should 
include MRSA coverage.16 Suspicion of infection with 
MRSA is based on the following criteria: (1) whether the 
infection is CA or HA, (2) individual risk factors for MRSA, 
and (3)   severity of the infection. In order to improve treat-
ment outcomes in S. aureus infections, surgical drainage 
and debridement, wound culture, and prompt initiation 
of appropriate   empirical antimicrobial therapy is recom-
mended.24,25 Definitive antimicrobial therapy in an MRSA 
infection is dependent on whether the infection is caused by 
CA-MRSA or HA-MRSA (Table 2).25
In February 2011, the Infectious Diseases Society of 
America (IDSA) published guidelines for the treatment of 
hospitalized adults and children with cSSTIs (synonymous 
with our definition of cSSSIs). The IDSA recommendation 
for adults includes empirical therapy with MRSA coverage 
and culturing for susceptibility data, in addition to surgical 
debridement and broad-spectrum antibiotics. Antibiotics 
used in empirical therapy include intravenous (IV) vanco-
mycin, daptomycin, telavancin, linezolid, and clindamycin. 
Oral linezolid and oral clindamycin are also empirical 
therapy options.
In hospitalized children with cSSSIs, the IDSA recom-
mends vancomycin. If the child is stable, nonbacteremic, 
and resistance to clindamycin is low, empirical intravenous 
clindamycin is an option. A transition to oral clindamycin 
therapy is indicated if the strain is susceptible to clindamycin. 
Intravenous or oral linezolid are also therapeutic alternatives 
for children.4
FDA-approved parenteral antimicrobial agents for the 
treatment of ABSSSIs (synonymous with our definition 
of cSSSIs) with anti-MRSA activity include vancomycin, 
quinupristin/dalfopristin, linezolid, daptomycin, telavancin, 
tigecycline, and ceftaroline.26 Vancomycin continues to be 
the first-line treatment for MRSA infections, as no other 
Table 1 Most common bacterial isolates identified in cSSSIs5–15
Gram-positive Gram-negative
Staphylococcus aureus: MSSA, MRSA Escherichia coli
Streptococcus pyogenes Pseudomonas aeruginosa
Enterococcus faecalis Klebsiella pneumoniae
Enterococcus faecium Proteus mirabilis
Coagulase-negative staphylococci Klebsiella oxytoca
Streptococcus agalactiae Enterobacteriaceae
Peptostreptococcus spp
Abbreviations: MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-
resistant Staphylococcus aureus.
Table 2 Recommended treatment for community-acquired MRSA 
versus hospital-acquired MRSA infection (including cSSSIs)4,24,25
CA-MRSA HA-MRSA
Usually not multidrug resistant Usually multidrug resistant
Susceptibility testing:  
trimethoprim–sulfamethoxazole  
(TMP-SMX), clindamycin, vancomycin
Susceptibility testing:  
vancomycin, rifampin,  
linezolid
Treatment: TMP-SMX,  
clindamycin, ciprofloxacin,  
gentamicin,a vancomycin, linezolid,  
daptomycin, or telavancin
Treatment: vancomycin,  
linezolid, daptomycin,  
tigecycline, or rifampin plus  
fusidic acid (where available)
Note: aOnly in combination with other agents.
Abbreviations:  MRSA,  methicillin-resistant  Staphylococcus  aureus;  TMP-SMX, 
trimethoprim-sulfamethoxazole.
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antimicrobial agent has proved to have superior efficacy.26–28 
Fusidic acid is marketed for the treatment of staphylococcal 
infections in at least 23 countries. Countries such as Canada, 
the UK, Ireland, and New Zealand have approved fusidic acid 
for use in the treatment of skin infections, including those 
caused by MRSA.29 A US multicenter Phase II, randomized, 
double-blind clinical trial comparing the efficacy and safety 
of an oral fusidic acid loading-dose regimen to oral linezolid 
in the treatment cSSSIs was conducted between August 2009 
and March 2010. The results of the study indicated fusidic 
acid had similar efficacy, safety, and tolerability as linezolid 
in the treatment of cSSSIs. This study demonstrates an 
attempt to introduce fusidic acid into the US market, pending 
additional Phase III clinical trials and FDA approval.30
Issues of resistance
The major pathogen of concern is MRSA due to its high 
prevalence of infection and multidrug-resistance.31–33 
US surveillance data over a 12-year period between 1992 
and 2004 indicated a 59.5% rate of methicillin resistance 
among S. aureus nosocomial infections in intensive care 
unit patients.34 MRSA has also become more common in 
infections in long-term care facility patients and in CA 
infections.6,35,36 The most commonly isolated MRSA clone in 
the US is MRSA USA300, identified in 99% of CA-MRSA 
isolates in one study.18 The spread of MRSA USA300 
has been reported around the world. Studies in Austria 
and   Canada reported identification of MRSA USA300 in 
CA-MRSA isolates (2.2% and 73.7%, respectively).33,37
In the US, there has been a rapid and alarming increase 
in CA-MRSA isolated from infections. US surveillance data 
over a 10-year period between 1998 and 2007 indicated a 
387.6% increase in CA-MRSA infection, rising from 7.3% 
in 1998 to 35.6% in 2007.32 Conversely, there has been 
a 27.9% decrease in HA-MRSA infection in the US over 
the same 10-year period, falling from 25.4% in 1998 to 
18.3% in 2007.32 Studies in the UK indicate the incidence of 
CA-MRSA infection is very low (,1%), although incidence 
does appear to be on the rise.38 Moreover, CA-MRSA has also 
been isolated from healthy individuals. One study in India 
found that 166 of 1000 (16.6%) healthy participants were 
carriers of CA-MRSA in their anterior nares.39
Consistent with US surveillance data between 1998 and 
2007, the Centers for Disease Control and Prevention (CDC) 
reported a 28% decrease of invasive MRSA infection in 
healthcare settings between 2005 and 2008. The CDC also 
reports a 17% decrease in CA-MRSA infection in people 
with recent exposure to health care settings. As such, the 
CDC recognizes the continued need to address this public 
health concern. In contrast, the CDC reported that CA-MRSA 
infection is increasing rapidly in the community.40
Resistance to vancomycin has also been reported, 
in   vancomycin-resistant enterococci (VRE) and the 
more recently emergent vancomycin-resistant S. aureus 
(VRSA).27,41,42 Enterococci demonstrate one of the high-
est rates of vancomycin resistance. A US study con-
ducted between 2007 and 2008 of isolates collected from 
hospitalized patients reported vancomycin resistance rates 
among Enterococcus faecalis and Enterococcus faecium 
were 5.4% and 75.4%, respectively.41 In Europe, a 5.1% rate 
of VRE was reported across 33 medical centers.43 A study 
in India reported a 1.4% rate of vancomycin resistance in 
S. aureus isolates collected from healthy individuals.39
Decreased susceptibility to vancomycin has also been 
observed in vancomycin-susceptible S. aureus (VSSA). In 
the presence of selection pressure, VSSA isolates are able to 
transform their cell wall to become less susceptible to vanco-
mycin, termed vancomycin-intermediate S. aureus (VISA). 
VISA isolates may progress through a precursor phenotype 
known as heteroresistant vancomycin-intermediate S. aureus 
(hVISA). A systematic review and meta-analysis evaluating 
the significance of hVISA isolates throughout the world 
reported that overall prevalence remains low at 1.3% of all 
MRSA isolates tested.44
Resistance to antimicrobial agents used in the treatment 
of cSSSIs is not limited to methicillin and vancomycin; 
there is also evidence of resistance to linezolid, daptomycin, 
streptogramins, ertapenem, fluoroquinolones, and glyco-
peptide antibiotics.28,31 In order to decrease resistance and 
cross-resistance development, optimizing antibiotic use 
through strict prescription habits as well as strict use of over-
the-counter topical antibiotic creams is key. The increasing 
prevalence of resistance to existing antimicrobial agents 
underscores not only the importance of judicious antibiotic 
use by clinicians, but also the need for the development of 
new antibiotics such as ceftaroline, an emerging cepha-
losporin that recently gained regulatory approval in the US 
for the treatment of cSSSIs.23,45
Ceftaroline
Ceftaroline fosamil (Teflaro®; Forest Laboratories, Inc, New 
York, NY) is a novel advanced-generation cephalosporin 
with broad-spectrum activity against Gram-positive, many 
Gram-negative, some anaerobic, and multidrug-resistant 
strains that cause serious CA and HA pneumonia and skin 
and skin-structure infections (Table 3).46–55 Ceftaroline is the 
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active metabolite of its prodrug form, ceftaroline   fosamil 
(herein referred to as ceftaroline). In several   clinical studies, 
ceftaroline demonstrated potent efficacy against common 
pathogens implicated in cSSSIs, including MRSA and 
β-hemolytic streptococci.10,14,15,56,57 In October 2010, the 
FDA approved ceftaroline for the treatment of CA bacterial 
pneumonia and cSSSIs, including MRSA-associated 
infections (Table 4).45
Mechanism of action
Ceftaroline is a bactericidal β-lactam antibiotic that targets 
and binds penicillin-binding proteins (PBPs) to inhibit 
cell wall synthesis through interference of peptidoglycan 
cross-linking.58 It binds with especially high affinity to the 
MRSA-associated PBP2a.59,60 Ceftaroline also binds with 
high affinity to the PBP2x possessed by penicillin-resistant 
Streptococcus pneumoniae (PRSP). Specifically, this bind-
ing inhibits transpeptidase or transglycosidase bacterial 
enzymes necessary for cell wall synthesis, thereby exerting 
its bactericidal effect.59 The 1,3-thiazole ring in ceftaroline’s 
molecular structure confers its anti-MRSA activity.61,62 
The 1,2,4-thiadiazole ring confers Gram-negative penetra-
tion and increased affinity for transpeptidase enzyme.59,62 
The phosphono group, only present in the prodrug, increases 
its solubility.59,62,63
Pharmacokinetics
Following parenteral administration, the water-soluble 
prodrug is hydrolyzed to its active metabolite, ceftaroline, by 
plasma phosphatases. It has a volume of distribution (Vd) of 
28.3 L into the total body water compartment.62 On average, 
20% of ceftaroline circulates bound to plasma proteins. It has 
a half-life of 2.6 hours.45
Ceftaroline mainly undergoes hydrolytic metabolism 
in the plasma. When incubated with pooled human liver 
microsomes, ceftaroline was metabolically stable, indicat-
ing that it is not a substrate for CYP450; therefore, there is 
minimal hepatic metabolism.64 The majority (about 88%) of 
the administered dose is eliminated from the body by renal 
glomerular filtration, followed by fecal excretion (about 6%), 
within 48 hours.63–65
Approximately half of the excreted drug is in active form, 
with a small quantity in inactive form (  ceftaroline-M-1).62 
No prodrug has been detected in the urine. This finding 
led to the conclusion of absolute biotransformation of the 
prodrug into its active metabolite, ceftaroline.62,65 In a single-
dose administration, ceftaroline has a renal clearance of 
95.6 mL/minute; administered in multiple doses, its renal 
clearance is 86.7 mL/minute.62
A number of studies in healthy adults demonstrated 
the absorption of ceftaroline when administered either 
Table 3 In vitro activity of ceftaroline against common Gram-
positive and Gram-negative bacterial isolates47,52,80,81
Gram-positive Gram-negative
Staphyloccocus aureus Enterobacteriaceae
  MSSA   Escherichia coli
  MRSA     Ceftazidime-susceptible
  vISA     ESBL-positive E. colia
  Linezolid resistant   Klebsiella pneumoniae
Coagulase-negative staphylococci     Ceftazidime-susceptible
Streptococcus pyogenes     ESBL-positive K. pneumoniaea
Streptococcus agalactiae   Enterobacter cloacae
Enterococcus faecalis     Proteus mirabilis
  vancomycin-susceptible   Citrobacter freundii
  vancomycin-resistant   Morganella morganii
Streptococcus pneumoniae     Serratia marcescens
  Penicillin susceptible   Shigella spp
  Penicillin intermediate Moraxella catarrhalis
  Penicillin resistant Haemophilus influenzae
  Levofloxacin resistant    β-lactamase positive, ampicillin 
resistant
  Multidrug resistant    β-lactamase negative, ampicillin 
resistant
Viridans group streptococci Pasteurella multocida
Pseudomonas aeruginosab
Notes:  aConflicting  data  for  activity  against  ESBL-positive  E.  coli  and  ESBL-positive 
Klebsiella pneumoniae;79–81 bconflicting data for activity against P. aeruginosa: in vitro studies 
show only limited activity whereas clinical studies show a high clinical cure rate.15,79–81
Abbreviations: MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-
resistant Staphylococcus aureus; vISA, vancomycin-intermediate Staphylococcus aureus; 
ESBL, extended-spectrum β-lactamase.
Table 4 Ceftarolinea in the treatment of cSSSIs in the USb
Dosage form Injection; powder for reconstitution 
Stable in: 1/2 NS, D5W, LR, NS
Usual dosage range 600 mg Iv every 12 hours for 5–14 days
Administration Slow Iv infusion over 60 minutes
Dosing for renal  
impairment
CLCr 31–50 mL/minute: administer 400 mg   
every 12 hours CLCr 15–30 mL/minute: 
administer 300 mg every 12 hours  
CLCr , 15 mL/minute and ESRD patients 
receiving hemodialysis: administer  
200 mg every 12 hours; should be given 
after hemodialysis, if applicable
Approved use Treatment of acute cSSSIs: caused by 
susceptible isolates of  Staphylococcus 
aureus (MSSA and MRSA), Streptococcus 
pyogenes, Streptococcus agalactiae, 
Escherichia coli, Klebsiella pneumoniae,  
and Klebsiella oxytoca
Notes: aAdvanced-generation cephalosporin antibiotic; bFDA-approved October 2010.
Abbreviations:  NS,  normal  saline;  D5W,  5%  dextrose  in  water;  LR,  lactated 
Ringer’s solution; Iv, intravenous; CLCr, creatinine clearance; ESRD, end-stage renal 
disease;  MSSA,  methicillin-susceptible  Staphylococcus  aureus;  MRSA,  methicillin-
resistant Staphylococcus aureus.
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  intravenously (IV) or intramuscularly (IM) in single or 
multiple doses.62 In single-dose studies, which administered 
ceftaroline (250, 500, 750, or 1000 mg) IV over 60   minutes, 
the maximum plasma concentration (Cmax) increased 
approximately in proportion to drug dose, 9.9, 16.5, 23.0, 
and 30.2 µg/mL, respectively.62 In multiple-dose studies, there 
was no accumulation of the drug when 300, 600, or 800 mg 
doses were administered at intervals of either 12 or 24 hours 
over the course of 7–14 days.62 In studies conducted by 
  Riccobene and colleagues comparing the pharmacokinetics 
of a single 600 mg IM dose to a single 600 mg IV dose, the 
Cmax attained were 8.5 µg/mL and 19.7 µg/mL, respectively. 
The time to reach maximum plasma concentration (tmax) for 
IM administration was 2 hours; the tmax for IV administration 
was only 0.98 hours.66
Studies by Ge and colleagues evaluated the similarities 
and differences in the pharmacokinetics of ceftaroline in 
individuals with normal renal function versus those with 
mild or moderate renal impairment during administration 
of ceftaroline 600 mg IV (Table 5).62,67 C max and tmax did 
not differ significantly among the three groups, whereas 
there was an increase in the area under the drug plasma 
concentration curve (AUC) and half-life (t1/2) in both the 
mild and moderate renal impairment groups in comparison 
to the normal renal function group. Furthermore, the renal 
clearance of ceftaroline decreased significantly in patients 
with mild and moderate renal impairment (30.8 mL/minute 
and 19.3 mL/minute, respectively) in comparison to patients 
with normal renal function (54.6 mL/minute).62
Another study by Riccobene and colleagues investigated 
the pharmacokinetics of ceftaroline in patients with end-stage 
renal disease.68 A 400 mg IV dose was administered over 
the course of 1 hour in two patient groups, one group before 
and one group after dialysis. Administering the dose prior 
to dialysis resulted in a Cmax similar to that of patients with 
normal renal function; however, administering the dose after 
dialysis resulted in a 74% increase in Cmax in comparison 
to patients with normal renal function. The AUC increased 
by 89% when ceftaroline was administered prior to dialysis 
and increased by 167% when administered after dialysis in 
comparison to patients with normal renal function. The t1/2 
also increased by 123% in both patient groups.68
In light of this clinical data, ceftaroline doses should 
be adjusted for patients with moderate renal impairment 
and those with end-stage renal disease.62,63,65,68 Ge and col-
leagues recommend ceftaroline 600 mg IV be infused over 
1 hour every 12 hours for patients with normal renal func-
tion and those with mild renal impairment; for patients with 
moderate renal impairment the dose should be reduced to 
400 mg IV .61,62,67 The FDA recommends 400 mg IV infused 
over 60 minutes every 12 hours for patients with mild renal 
impairment, 300 mg IV for patients with moderate renal 
impairment, and 200 mg IV for patients with end-stage 
renal disease, including those undergoing hemodialysis 
(Table 4).45
Pharmacodynamics
A mouse model study of thigh and lung infection conducted 
by Andes and Craig determined the pharmacokinetic–
pharmacodynamic (PK–PD) index to predict the efficacy of 
ceftaroline against MRSA and Gram-negative bacilli.69 The 
percentage of time the serum concentrations were above the 
minimum inhibitory concentration (%T . MIC) was the 
PK–PD that best correlated with drug efficacy.59 The MIC 
is the lowest concentration that will inhibit visible growth of 
bacteria after overnight incubation. A lower MIC indicates 
a more efficacious antimicrobial agent.70 Andes and Craig 
reported a mean %T . MIC of 39% for S. pneumoniae, 21% 
for MRSA, and 28% for E. coli and Klebsiella pneumoniae 
combined to achieve a bacteriostatic effect. A dose of 
64.1 mg/kg/24 hours and a %T . MIC of 50% was necessary 
to achieve a 2-log10 reduction against MRSA.69
An in vitro study using a PK–PD model evaluated 
  ceftaroline 600 mg MRSA and hVISA activity every 8 hours 
and 12 hours in comparison to vancomycin 1000 mg activity 
every 12 hours over a 72-hour period.71 Ceftaroline proved 
superior to vancomycin against all isolates, except one to 
which it was equivalent; no emergent drug-resistant isolates 
were observed.71 Further, in a rabbit endocarditis model 
study, ceftaroline demonstrated a high bactericidal effect, 
Table 5 Pharmacokinetics in patients with renal impairment: single-dose ceftaroline 600 mg Iv67
Renal status  
(CLCr mL/minute)
t1/2  
(hours)
Cmax  
(μg/mL)
tmax  
(hours)
AUC  
(μg ⋅ hour/mL)
CLR  
(mL/minute)
Normal (CLCr . 80) 2.84 27.6 0.97 35.6 54.6
Mild (CLCr . 50–80) 3.61 27.7 0.99 89.4 30.8
Moderate (CLCr . 30–50) 4.49 30.5 1.1 114 19.3
Abbreviations:  CLCr,  creatinine  clearance;  t1/2,  half-life;  Cmax,  maximum  plasma  concentration;  tmax,  time  to  maximum  plasma  concentration;  AUC,  area  under  the 
concentration–time curve; CLR, renal clearance.
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significant killing of bacteria in aortic vegetations, and 
superior bactericidal activity against hVISA compared to 
vancomycin.49 Treatment of the infected vegetations with 
ceftaroline 10 mg/kg IV every 12 hours resulted in 90% sterile 
vegetations after 4 days in comparison to vancomycin constant 
IV infusion, which resulted in 67% sterile vegetations.49
Clinical trials of ceftaroline in cSSSIs
Efficacy
The efficacy of ceftaroline against bacteria that cause 
cSSSIs is well established in multiple clinical studies, one 
Phase II and two identical Phase III trials. A Phase II trial 
consisting of a total of 100 patients evaluated ceftaroline 
versus standard therapy (defined as vancomycin with or 
without adjunctive aztreonam in the study) in the treatment of 
cSSSIs (67 patients vs 33 patients, respectively). Ceftaroline 
was administered at a dose of 600 mg IV every 12 hours 
for 7–14 days, and vancomycin was administered at a 
dose of 1 g IV every 12 hours with or without adjunctive 
aztreonam at a dose of 1 g IV every 8 hours for 7–14 days. 
There was a total of 88 patients in the clinically evaluable 
(CE) population. Clinical cure rates for ceftaroline in CE 
patients at test-of-cure (TOC) and end-of-therapy (EOT) 
visits were high (96.7% and 98.4%, respectively).54 Clinical 
cure rates for standard therapy in CE patients at TOC and 
EOT visits were lower in both instances (88.9% and 96.3%, 
respectively). Among the microbiologically evaluable (ME) 
patient population (ie, clinically evaluable and having had 
at least one susceptible pathogen isolated at baseline), 
ceftaroline demonstrated a higher microbiological success 
rate than standard therapy (95.2% vs 85.7%, respectively).54 
The Phase II trial included adults diagnosed with skin and 
skin-structure infections if the infection involved deep soft 
tissue, required significant surgical intervention, or the 
infection had developed in a lower extremity in a patient with 
diabetes mellitus or peripheral vascular disease.54 The TOC 
assessments were conducted 8–14 days following the last 
administered dose. The mean length of therapy was similar 
for both the ceftaroline and standard therapy groups (7.8 days 
and 8.0 days, respectively).54
Two identical Phase III, multicenter, international, 
randomized, double-blind clinical trials (CANVAS 1 and 
CANVAS 2) evaluated ceftaroline versus vancomycin plus 
aztreonam in the treatment of cSSSIs (Table 6).10,15 Combining 
CANVAS 1 and 2 data, 701 patients were administered 
ceftaroline 600 mg IV every 12 hours for 5–14 days 
and 695 patients were administered vancomycin 1 g IV plus 
aztreonam 1 g IV every 12 hours for 5–14 days. Both Phase III 
trials included patients $18 years of age with a diagnosis of 
cSSSI that required $5 days of IV antibiotic therapy. The 
primary study outcome was clinical cure, defined as total 
resolution of all signs and symptoms of baseline infection or 
improvement such that no further antimicrobial treatment was 
needed at the TOC visit (8–15 days after the last administered 
dose).10,15 The mean length of therapy for CANVAS 1 and 2 
was similar (7 days and 6.5 days, respectively).10,15
The CANVAS 1 and 2 trials demonstrated similar 
cure rates for ceftaroline and vancomycin plus aztreonam 
in the CE and ME populations, as well as the modified 
intent-to-treat (MITT) population, which consisted of patients 
who received any amount of study medication. In CANVAS 
1, clinical cure rates were similar for ceftaroline and 
vancomycin plus aztreonam in the CE population (91.1% vs   
93.3%, respectively), ME population (92.2% vs 94.7%, 
respectively), and the MITT population (86.6% vs 85.6%, 
respectively). In CANVAS 2, clinical cure rates were also 
similar for ceftaroline and vancomycin plus aztreonam in 
the CE population (92.2% vs 92.1%, respectively), ME 
population (93.3% vs 94.1%, respectively), and the MITT 
population (85.1% vs 85.5%, respectively) (Table 6).
Combined data from CANVAS 1 and 2 show a similar cure 
rate in CE patients with diabetes mellitus or peripheral vascu-
lar disease treated with ceftaroline versus vancomycin plus 
aztreonam (86.7%–91.1% and 87.2%–93.4%,   respectively). 
Table 6 Clinical cure rates by population in Phase III CANvAS 1 and 2 trials10,15
CANVAS 1  
Clinical cure rate %
CANVAS 2  
Clinical cure rate %
Ceftarolinea Vancomycin plus aztreonamb Ceftarolinea Vancomycin plus aztreonamb
Population
CE 91.1 93.3 92.2 92.1
ME 92.2 94.7 93.3 94.1
MITT 86.6 85.6 85.1 85.5
Notes: a600 mg of ceftaroline intravenously every 12 hours for 5–14 days; b1 g of vancomycin plus 1 g of aztreonam intravenously every 12 hours for 5–14 days.
Abbreviations: CANVAS, ceftaroline versus vancomycin in skin and skin structure infections; MITT, modified intent-to-treat; CE, clinically evaluable; ME, microbiologically 
evaluable.
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The clinical cure rate was higher in CE patients with a lower 
extremity infection and either diabetes mellitus or periph-
eral vascular disease treated with ceftaroline in comparison 
to vancomycin plus aztreonam (100% and 81.8%–94.7%, 
respectively).10,15
The CANVAS trials demonstrated similar clinical 
cure rates for cSSSIs specifically caused by MRSA. In 
CANVAS 1, clinical cure rates for MRSA cSSSIs in the cef-
taroline and vancomycin plus aztreonam groups were 95.1% 
and 95.2%, respectively; in CANVAS 2, they were 91.4% 
and 93.3%, respectively. Ceftaroline clinical cure rates by 
specific pathogen involved are reported in Table 7. It should 
be noted that ceftaroline demonstrated a 71.4% clinical cure 
rate against P . aeruginosa in the ME population in CANVAS 
2 but did not show any activity against P . aeruginosa in either 
the Phase II or CANVAS 1 trials.15
Ceftaroline MIC90 values, the lowest concentration 
at which 90% of the bacteria are inhibited, for the most 
common pathogens encountered in cSSSIs are reported 
in Table 8.10,14,15 In CANVAS 1 and 2, the most common 
pathogen was S. aureus, which appeared in 75% and 82% of 
isolates, respectively. Of these S. aureus isolates, MRSA was 
identified in 43% and 30%, respectively.10,15 S. aureus isolates 
were susceptible to ceftaroline at a lower MIC90 (#0.5 mg/L) 
Table 7 Ceftaroline clinical cure rates by pathogen reported in Phase II and III clinical trials10,15,54
Pathogen  Ceftaroline clinical cure rate %   
(CE population)
Ceftaroline clinical cure rate %  
(ME population)
Phase II CANVAS 1a CANVAS 2a
Gram-positive
Staphylococcus aureus 96.7 – 93.3
  MSSA 100 91.3 94.4
  MRSA 80 95.1 91.4
Staphylococcus haemolyticus 100 – –
Streptococci – – –
  S. pyogenes 100 100 100
  S. agalactiae 100 93.8 100
  Enterococcus faecalis 100 92.9 63.6
  Enterococcus faecium 0 – –
  Group C streptococci 100 – –
  viridans group 100 – –
  S. intermedius 100 – 100
  S. anginosus 100 – 100
  S. anginosus/“milleri” 100 – –
  S. constellatus – – 100
  S. dysgalactiae – – 100
  S. oralis 100 – –
Peptostreptococcus prevotii 100 – –
Pediococcus spp 100 – –
Monomicrobial Gram-positive infections – – 94.4
Polymicrobial Gram-positive infections – – 92.3
Gram-negative
Enterobacteriaceae – – 83.3
  Escherichia coli – 90 100
  Klebsiella pneumoniae 100 90.9 100
  Klebsiella oxytoca – – 100
  Enterobacter cloacae 100 – 100
  Proteus mirabilis 0 70 60
  Citrobacter freundii 0 – –
  Morganella morganii – – –
  Serratia marcescens – – 100
  Pseudomonas aeruginosa – – 71.4
Monomicrobial Gram-negative infections – – 100
Polymicrobial Gram-negative infections – – 50
Mixed Gram-positive and Gram-negative infections – – 88.9
Note: aPhase III clinical trials.
Abbreviations: CE, clinically evaluable; ME, microbiologically evaluable; MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus.
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compared to vancomycin (#1.0 mg/L).10,15 Ceftaroline also 
demonstrated inhibitory activity at a lower MIC90 against 
S. pyogenes and Streptococcus agalactiae versus vancomycin 
alone (Table 8). However, ceftaroline showed conflicting 
results against E. faecalis; it had a higher MIC90 against 
E. faecalis in CANVAS 1 yet demonstrated a lower MIC90 
versus vancomycin alone in the Phase II and CANVAS 2 
trials.10,14,15
A 2008 international surveillance study by Jones and 
colleagues evaluated ceftaroline activity against 14,169 isolates 
collected from cSSSI patients in the US and Europe. In US 
isolates, the study indicated ceftaroline activity against 2254 
MRSA isolates (MIC90, 1 mg/L). In European isolates, ceftaroline 
was active against 734 MRSA isolates (MIC90, 2 mg/L).14 The 
MIC90 for methicillin-susceptible S. aureus (MSSA) was 
0.25–0.5 mg/L. Ceftaroline was also active against coagulase-
negative staphylococci (MIC90, 0.5–1 mg/L), E. faecalis (MIC90, 
2 mg/L), β-hemolytic streptococci (MIC90, 0.015–0.03 mg/L), 
viridans group streptococci (MIC90, 0.012–0.25 mg/L), and 
E. coli (MIC90, 0.25 to .16 mg/L).14
Overall, in clinical trials ceftaroline proved efficacious 
in the treatment of cSSSIs, achieving high clinical cure rates 
and demonstrating high bactericidal activity against Gram-
positive and Gram-negative pathogens, including MRSA. 
Furthermore, ceftaroline demonstrated noninferiority to 
vancomycin plus aztreonam standard therapy.10,14,15
Safety and tolerability
Ceftaroline has a margin of safety and tolerability consis-
tent with that of other cephalosporins.54 In the Phase II and 
CANVAS 1 and 2 clinical trials, ceftaroline demonstrated 
low or comparable incidence of adverse events to that 
of current standard therapy, with minimal or no effects 
on renal and hepatic function.10,15,54,57 The most common 
adverse events were nausea, diarrhea, headache, rash, and 
pruritis, with only 1.5%–6.5% of patients reporting any one 
of these symptoms during the course of therapy (Table 9). 
The   majority (70.8%–72.3%) of patients reported adverse 
events to be mild.10,15,54
An integrated safety summary of CANVAS 1 and 2 indi-
cated only 28.3% of patients reported mild adverse symp-
toms, with 55.3% of patients reporting no symptoms at all.57 
Elevated blood creatine phosphokinase was reported as a 
laboratory finding without clinically evident muscle or car-
diac abnormalities.54 There was also no clinical evidence of 
hemolytic anemia.57 The percentage of patients with elevated 
alanine aminotransferase (ALT) or aspartate aminotrans-
ferase (AST) was low and not a cause for concern.54,57
A small percentage of patients (4.1%–5.1%) devel-
oped a severe adverse event. An even smaller number of 
these patients discontinued treatment due to the severe 
adverse event. In the Phase II trial, all severe adverse events 
were resolved with no patient discontinuing treatment.10,15,54,57 
The CANVAS 1 trial reported three deaths during the course 
of treatment; however, the causes of death were unrelated to 
the therapy or the cSSSI.10 Overall, the IV infusion of ceftaro-
line was well tolerated, with only 3% of patients reporting 
  discomfort at the site of infusion in the Phase II trial.54
Integrated data from the CANVAS trials shows a 
smaller percentage of patients administered ceftaroline in 
comparison to vancomycin plus aztreonam experienced 
an increase in serum creatinine and blood urea nitrogen 
Table 8 MIC90 values reported for ceftaroline, vancomycin, and aztreonam activity against Gram-positive and Gram-negative pathogens 
commonly found in cSSSIs10,14,15
Pathogen MIC90 (mg/L)
Ceftaroline  
CANVAS 1
Ceftaroline  
CANVAS 2
Ceftaroline  
Jones et al
Vancomycin Aztreonam
Staphylococcus aureus (MSSA + MRSA) 0.5 0.5 1.0 1.0 –
  MSSA 0.25 0.25 0.25–0.5 1.0 –
  MRSA 1.0 0.5 1.0 1.0 –
CoNS – – 0.5 – –
Streptococcus pyogenes #0.004 #0.004 – 0.5 –
Streptococcus agalactiae 0.015 – – 0.5 –
Enterococcus faecalis 8.0 1.0 2.0 2.0 –
β-hemolytic streptococci – – 0.015–0.03 – –
Viridans streptococci – – 0.012–0.25 – –
Escherichia coli 1.0 0.5 0.25 to .16 – 0.12
Klebsiella pneumoniae .16 – – – .32
Proteus mirabilis .16 NA – – #0.03–0.25
Abbreviations: MIC90, minimum inhibitory concentration at which 90% of the isolates are inhibited; CoNS, coagulase-negative staphylococci; MSSA, methicillin-susceptible 
Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus.
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(0.9% and 0.3% vs 2.1% and 1.2%, respectively) demonstrating 
that ceftaroline has less impact on renal function compared 
to standard treatment.57 One patient developed acute renal 
failure, however, it was unclear whether the event occurred 
as a result of the treatment.57 Potential for hepatic damage 
was also evaluated. In both the ceftaroline and vancomycin 
plus aztreonam groups, no patients had an increase in ALT or 
AST greater than threefold above the upper limit of normal, 
less than twofold increase in alkaline phosphatase above the 
upper limit of normal, or a greater than twofold increase in 
bilirubin above the upper limit of normal; thus, no hepatic 
damage was noted in any patient.57
In the CANVAS trials, three patients in the ceftaroline group 
were reported to have Clostridium difficile gastrointestinal 
infection versus only one in the vancomycin plus aztreonam 
groups.57 In the Phase II trial, no patients discontinued treatment 
due to noncompliance or unsatisfactory therapeutic response.54 
In CANVAS 1, only one patient discontinued treatment due 
to noncompliance and no patients discontinued due to lack 
of clinical progress.10 Similarly in CANVAS 2, no patients 
discontinued treatment due to noncompliance, however, 
two patients discontinued due to lack of clinical progress.15
In summary, clinical trial data demonstrated ceftaroline is 
generally safe and well tolerated in the treatment of   cSSSIs. 
The number of patients reporting adverse events related to the 
course of therapy was low, with the majority of these adverse 
events being mild. There was also minimal or no effect on 
renal and hepatic function, making ceftaroline a safe option 
in the treatment of cSSSIs.
Advantages and disadvantages  
of ceftaroline in cSSSIs
Problems with current cSSSIs 
therapeutics
The emergence of vancomycin resistance among bacterial 
pathogens associated with cSSSIs is a growing concern in the 
treatment of these infections.41 Vancomycin also carries the risk 
for nephrotoxicity as well as development of red-man syndrome 
when administered too rapidly.72,73 Disadvantages of linezolid 
Table 9 Most common adverse events reported for ceftaroline 600 mg Iv every 12 hours for 5–14 days treatment10,15,54,57
% of patients (AE) % of patients (TEAE) 
Phase II CANVAS 1 CANVAS 2 Integrated CANVAS  
summary
Most common
  Nausea 6.0 5.7 6.2 5.9
  Diarrhea – 3.4 6.5 4.9
  Headache 6.0 5.1 5.3 5.2
  Rash 1.5 – – 3.2
  Pruritis – 3.1 3.8 3.5
Elevated blood CPK 7.5 – – –
Crystals in urine 9.0 – – –
Elevated ALT 6.0 – – 1.2
Elevated AST 6.0 – – 1.0
Patients with a SAE 5.1 4.6 4.1 4.3
Patients who died during study 0 0.9 0 0
Patients discontinued due  
to AE or TEAE
3.0 3.7 2.3 3.0
Infusion site erythema/swelling 3.1 – – 1.0
Renal abnormalities
    Serum creatinine .1.5 mg/dL  
and .50% increase
– – – 0.9
    BUN .1.5X ULN and .50% increase – – – 0.3
    Creatinine clearance .50% increase – – – 0.4
Liver function abnormalities
    ALT or AST . 3× ULN, ALP  
,2× ULN and total bilirubin 
.2× ULN
– – – 0
Positive direct Coombs’ test – Ceftaroline  
Group . standard  
therapy group
Ceftaroline  
Group . standard  
therapy group
11.6
Abbreviations:  AE,  adverse  event;  CPK,  creatine  phosphokinase;  ALT,  alanine  aminotransferase;  AST,  aspartate  aminotransferase;  SAE,  severe  adverse  event;   
TEAE, treatment-emergent adverse event; BUN, blood urea nitrogen; ULN, upper limit of normal; ALP, alkaline phosphatase.
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include bacteriostatic activity (rather than bactericidal) 
against staphylococci and enterococci, potential toxicity with 
prolonged therapy, myelosuppression, and monoamine oxidase 
inhibition.3,74 Daptomycin lacks activity against Gram-negative 
pathogens, can cause muscular toxicity, and must be used with 
caution in patients taking statins.74,75 Similarly, telavancin 
lacks activity against Gram-negative pathogens.76 Telavancin 
should also be avoided in patients with cardiac disease and 
those who undergo routine coagulation tests, since telavancin 
produces false-positive blood test abnormalities.42 Tigecycline 
is only bacteriostatic, can cause digestive system side effects, 
tooth discoloration, acute pancreatitis, and is contraindicated 
in pregnant women.8,77 Tigecycline must also be used with 
caution in patients with hepatic impairment or intestinal 
perforation.78
Advantages of ceftaroline in cSSSIs
Ceftaroline is the first cephalosporin with a high clinical cure rate 
for cSSSIs caused by CA-MRSA and HA-MRSA.10,14,15,47,53,54 
It has broad-spectrum bactericidal activity with high activity 
against many opportunistic pathogens. Clinical trials reported 
that the most commonly encountered adverse events were 
mild, with very few patients experiencing swelling or pain at 
the infusion site.10,15,54 Further, few patients experienced renal 
or hepatic abnormalities related to ceftaroline therapy, and 
thus, ceftaroline is recommended for use in patients with renal 
impairment at adjusted doses. Although the pharmacokinetics 
of ceftaroline in patients with hepatic impairment have not been 
established, its minimal hepatic metabolism suggests systemic 
clearance of the drug is not significantly affected by hepatic 
impairment. Additionally, ceftaroline demonstrated very few 
clinically evident muscle or cardiac abnormalities.10,15,54
Disadvantages of ceftaroline in cSSSIs
There is no consensus on ceftaroline’s activity against certain 
extended-spectrum β-lactamase-producing (ESBL) strains. 
Biek and colleagues reported that ceftaroline is inactive 
against ESBL-producing Enterobacteriaceae.79 A different 
study, however, demonstrated that ceftaroline does possess 
activity against ESBL-producing E. coli and K. pneumoniae 
strains at high concentrations (MIC90 of $32 µg/mL).80 
  Similarly, another study showed ceftaroline to be active at 
high MICs against ESBL-producing strains regardless of 
species.81 Most in vitro studies have also shown that ceftaro-
line has only limited activity against P . aeruginosa.42,79–81 
  However in the CANVAS 2 clinical trial, ceftaroline dem-
onstrated a high clinical cure rate against P . aeruginosa in 
five of seven (71.4%) patients in the ME population.15
Additionally, there are no well-controlled clinical trials 
evaluating ceftaroline use in pregnant women, and thus, 
its use in pregnancy should only occur if the benefit justifies 
the potential risk to the fetus. The safety and effectiveness of 
ceftaroline in the pediatric population, patients receiving 
  systemic corticosteroid therapy, patients with HIV, and 
patients with a recent history of chemotherapy or radiation 
therapy has also not been established.15,64
Patient considerations
Although ceftaroline has demonstrated a high clinical cure 
rate in cSSSIs, especially when MRSA strains are involved, 
to date there are no data available regarding patient compli-
ance and satisfaction during ceftaroline therapy or quality of 
life following treatment. In the Phase II and CANVAS trials, 
a large percentage of patients presented with severe signs and 
symptoms at baseline, which included fever, major abscesses, 
extensive cellulitis, or complicating factors such as diabetes 
mellitus and peripheral vascular disease.10,15,54 A severe clini-
cal presentation and the need for hospital-based treatment 
could be determinants leading to high patient compliance and 
satisfaction; however, future studies are necessary to examine 
these patient-related factors and the impact of ceftaroline 
treatment on quality of life.
The cost of ceftaroline is US$41 for either a 400 mg 
or 600 mg vial. The total cost of ceftaroline treatment 
for a patient with normal renal function is US$82/day or 
US$574/7-day course of treatment.58
Conclusion
Ceftaroline is a potent, safe, and effective new cephalosporin 
for the treatment of cSSSIs, including those caused by CA-
MRSA and HA-MRSA. Because of its broad-spectrum 
coverage, bactericidal activity, tolerability, and minimal side 
effect profile, ceftaroline is an attractive first-line therapeutic 
choice for the treatment of cSSSIs, including infections in 
which MRSA is suspected.
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